RELIANCE GENEMEDIX PLC

RELIANCE GENEMEDIX PLC

Previous company name
GENEMEDIX PLC
Name change date
10/16/2008
Company Overview
GeneMedix PLC, with headquarters in Newmarket, is engaged in the development, manufacture and distribution of multi-source biopharmaceuticals, generic versions of therapeutic proteins. GeneMedix was founded in 1997 by Dr Kim Tan and Dr Hong-Hoi Ting, with the Shanghai Institute of Biochemistry acting as a major shareholder.
GeneMedix’s products include Neustim; Interferon alpha, used in the treatment of hepatitis C and hepatitis B, both alone and in combination with oral antiviral agents; Erythropoietin, used to treat severe anaemia (low red blood cell count), associated with chronic renal failure and in cancer patients undergoing chemotherapy; Granulocyte Colony Stimulating Factor, used mainly for the treatment of chemotherapy induced neutropenia, and acts by stimulating neutrophil production; Insulin; Interferon gamma; Interleukin-2; EGF; and other proteins.
It is a UK based, globally focused biopharmaceutical company, specialising in the development and manufacture of cost effective treatments for some of the world’s most serious diseases. The company strives to build on its core expertise of protein development scale-up and manufacture as the company grows, and to add value to the basic proteins, by developing new formulations and delivery methods or researching new indications where this shows benefit to patients.
The company has strategic alliances with Kryonix, Antares Pharma, Gland Pharma, Hovid, and Shanghai Institute of Biochemistry & Cell Biology (IBCB), which allow GeneMedix to access drug delivery technologies, distribution channels, secondary manufacture, intellectual property and cell lines.
The company has biopharmaceutical manufacturing facilities in Ireland (erythropoietin [EPO] using proven expression and purification systems) and in China (GM-CSF [granulocyte macrophage-colony stimulating factor] process). It has an intention to begin the design and construction of additional manufacturing facilities in Spain and Malaysia. Managed independently, but reporting to Global Manufacturing at GeneMedix’s headquarters in the UK, these sites are operated to appropriate Good Manufacturing Practice [cGMP] standards.
Business Summary
The principal activities of the Company and Group are the development, manufacture and distribution of comparable biotechnology pharmaceuticals, which are a generic version of innovative therapeutic proteins.
Description and history
The principal activities of the Company and Group are the development, manufacture and distribution of comparable biotechnology pharmaceuticals, which are a generic version of innovative therapeutic proteins.

History:

The Company was incorporated on 18 November 1997 and listed on the London Stock Exchange on 16 February 2007.

Founded through a collaboration and joint venture with the Shanghai Institute of Biochemistry and Cell Biology [IBCB], GeneMedix sponsored research and subsequently acquired rights to the manufacture and sale of specified biopharmaceutical proteins using recombinant DNA technology.

February 2007
Acquisition by Reliance Life Sciences completed

January 2007
Acquisition by Reliance Life Sciences approved at EGM

August 2006
Letter of Intent signed with Reliance Life Sciences (RLS) for RLS to acquire a controlling interest in GeneMedix through a subscription of new shares.

October 2005
Restructuring programme commenced to re-finance the business and attract new corporate partners.

September 2005
Letter of intent signed to sell Chinese facility and restructuring programme announced

July 2005
G-CSF deal signed with CJ Pharma

Draft guidelines published by EMEA for EPO, G-CSF and HGH

October 2004
Signed Southridge financing deal to raise up to $10 million equity over 3 years

June 2004
Agreement with Kryonix to supply GM-CSF to Russia

April 2004
New pharmaceutical directive introduced into European Union that establishes legal pathway for the registration of “follow-on” biologics

January 2004
Level One ADR programme established on NASDAQ and appointed Global Markets Capital for strategic M&A

June 2003
Letter of Intent signed with Penang Development Corporation to establish a Biotechnology Company in Penang, Malaysia for the development, manufacture and commercialisation of human insulin.

March 2003
New collaboration with Antares Pharma announced, with the aim of improving device technology for GeneMedix products.

February 2003
Formation of a Joint Venture with Antibioticos Group, involving construction of a state-of-the-art fermentation facility in Europe for contract manufacture of three products. Antibioticos is a worldwide market leader in the development and production of intermediates for the pharmaceutical industry.

July 2002
GeneMedix signs a Development Agreement for interferon alfa-2b with SkyePharma plc, who employ leading drug delivery technology to develop easier-to-use and more effective formulations of drugs.

June 2002
Official opening of GeneMedix plc’s new manufacturing facility in Tullamore, Ireland. Guests included Brian Cowen, TD, Minister for Foreign Affairs in Ireland, pictured to the right with Paul Edwards, GeneMedix CEO, and Conor O’Dea, General Manager [Ireland].

May 2002
Agreements for Manufacturing and for Sales & Distribution signed with Gland Pharma Ltd, one of India’s leading suppliers of speciality pharmaceutical products.

January 2002
Announcement of first product sales in China for GeneMedix plc’s initial product, Neustim(TM).

2001
Leading Malaysian pharmaceutical manufacturer, Hovid SDN BhD, is appointed to distribute, market and sell GeneMedix’s products within Malaysia and other ASEAN countries.

GeneMedix received full regulatory approval from the Chinese State Drug Administration [SDA] to sell granulocyte macrophage colony stimulating factor [GM-CSF].

The company announces its plans to open a second manufacturing facility, in Ireland, for the manufacture of recombinant erythropoietin.

2000
Highlights included the acquisition of the company’s first manufacturing facility, based in China. Earlier in the year, GeneMedix achieved a dual listing on the London and Singapore Stock Exchanges, raising Ј20m in addition to its initial funding. The company also recruited its core management team during this year.

1999
The first round of external funding for the company was sought, and Paul Edwards [formerly VP of Genzyme, UK] was appointed as GeneMedix plc’s CEO.

1997
GeneMedix was founded as a company by Dr Kim Tan and Dr Hong-Hoi Ting [now Director, Asia for GeneMedix plc], with the Shanghai Institute of Biochemistry acting as a major shareholder.

Change of name
The company changed name to Reliance GeneMedix plc with effective on 16 October 2008.

Founded by Dr Kim Tan and Dr Hong-Hoi Ting, with the Shanghai Institute of Biochemistry acting as a major shareholder

Business Line
Develops, manufactures and distributes multi source biopharmaceuticals, generic versions of therapeutic proteins
Subsidiary
BIOMETRIX MARKETING PRIVATE LIMITED
Advisor
DELOITTE & TOUCHE LLP
IPO date
2/16/2007
US SIC Code
2834
Company Address
8th Floor
105, Wigmore Street
City province or state postal code
W1U 1QY, LONDON
Phone: +44 353 5793 23572
Fax: +44 353 5793 23592
Country address: UNITED KINGDOM
Website url: www.genemedix.com